ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Other EventsItem 8.01 Other Events.
On October31st, 2018, Aralez Pharmaceuticals Inc. and its debtor subsidiaries filed a monthly operating report for the period from September1, 2018 to September30, 2018 (the “Monthly Operating Report”) with the United States Bankruptcy Court for the Southern District of New York. A copy of the Monthly Operating Report is attached as Exhibit99.1 to this Current Report on Form8-K and is incorporated by reference into this item 8.01.
Aralez Pharmaceuticals Inc. ExhibitEX-99.1 2 a18-39498_1ex99d1.htm EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re ARALEZ PHARMACEUTICALS US INC.,…To view the full exhibit click
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
An ad to help with our costs